Lonidamine in metastatic breast cancer

Riccardo Rosso, Domenico Amoroso, Giovanni Gardin, Loredana Miglietta, Tiziana Guido, Maurizio Pace, Lazzaro Repetto, Paolo Pronzato

Research output: Contribution to journalArticlepeer-review


Lonidamine belongs to a new class of antineoplastics agents, since it does interfere with cell energy processes. When administered as single agent in metastatic breast cancer, it produces moderate therapeutic effects. The pattern of toxicity includes myalgias, asthenia, testicular pain, and gastrointestinal discomfort. No myelosuppression was demonstrated in phase I-II studies. Since the peculiar mechanism of action and side effects are not overlapping with those of standard chemotherapeutic agents, combination of lonidamine with chemotherapy is currently under investigation in advanced breast cancer. Moreover, the potentiation of radiotherapy by lonidamine could be of interest in palliating symptomatic lesions from breast cancer.

Original languageEnglish
Pages (from-to)62-65
Number of pages4
JournalSeminars in Oncology
Issue number2 SUPPL. 4
Publication statusPublished - 1991

ASJC Scopus subject areas

  • Oncology


Dive into the research topics of 'Lonidamine in metastatic breast cancer'. Together they form a unique fingerprint.

Cite this